ArticleArthritis care & research2025
Analysis of the Longitudinal Behavior of Serum Levels of Soluble Flt1 and Placental Growth Factor in Pregnant Patients With Systemic Lupus Erythematosus.
Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study analyzed longitudinal trajectories of soluble Flt1 (sFlt1) levels, placenta growth factor (PlGF) levels, and sFlt1:PlGF ratios in a cohort of pregnant patients with systemic lupus erythematosus (SLE).
methodsBlood samples were collected (14-18, 24-26, 30-32, 34-36, and 38-40 weeks), stored at -80°C, and evaluated for serum levels of sFlt1, PlGF, and sFlt1:PlGF ratios. Patients were classified as inactive SLE (Systemic Lupus Erythematosus Pregnancy Disease Activity Index [SLEPDAI] <4), active disease (SLEPDAI ≥4), or preeclampsia (PE). Medians and interquartile ranges were calculated for each group, and linear models with random effects were used.
resultsA total of 527 samples were obtained from 163 patients, and all patients were subsequently classified as having inactive disease (109 patients [66.9%]), active disease (33 patients [20.2%]), and inactive disease with PE (21 patients [12.9%]). In exploratory analysis, patients with PE had higher mean serum levels of sFlt1 and sFlt1:PlGF ratios and lower PlGF levels than patients with inactive and active SLE (P = 0.01 to P < 0.001). Using linear models with random effects, there was no significant differences in mean serum levels of these angiogenic markers comparing inactive and active disease. Patients with PE showed a marked increase in sFlt1 levels from the 24th week, constantly low PlGF levels from the 14th week, and progressive increase of sFlt1:PlGF ratio during pregnancy. All these differences were statistically significant compared to the groups without PE.
conclusionPregnant patients with SLE who developed PE had higher sFlt1 levels and sFlt1:PlGF ratios and lower PlGF levels, and these last two changes were detected at the beginning of second trimester, before clinical manifestation. SLE activity did not interfere with longitudinal behavior of these angiogenic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.